Aftertreated Polymer (e.g., Grafting, Blocking, Etc.) Patents (Class 424/78.17)
-
Patent number: 8790632Abstract: Tissue adhesives formed by reacting poly(hydroxylic) compounds derivatized with acetoacetate groups and/or polyamino compounds derivatized with acetoacetamide groups with an amino-functional crosslinking compound are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; and anti-adhesive applications are described.Type: GrantFiled: October 5, 2005Date of Patent: July 29, 2014Assignee: Actamax Surgical Materials, LLCInventor: Samuel David Arthur
-
Patent number: 8790631Abstract: The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR? group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R? or —RNS03R? in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R? denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same.Type: GrantFiled: October 28, 2004Date of Patent: July 29, 2014Assignees: Organes Tissus Regeneration Reparation Replacement—OTR3Inventors: Denis Barritault, Veronique Barbier-Chassefiere
-
Patent number: 8790633Abstract: The invention relates to a polymer comprising a segment of Formula (I): wherein, R is either absent or a linking group, n is an integer greater than 0; and m is an integer from 1 to 6.Type: GrantFiled: October 28, 2010Date of Patent: July 29, 2014Assignee: Agency for Science, Technology and ResearchInventors: Jackie Y. Ying, Subramanian T. Selvan, Nandanan Erathodiyil, Alex Wei Haw Lin
-
Publication number: 20140205542Abstract: Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.Type: ApplicationFiled: March 25, 2014Publication date: July 24, 2014Applicants: Lahey Clinic, Inc., Genzyme CorporationInventors: Jean-Marie Vogel, James A. Wilkie, Peter N. Madras
-
Patent number: 8785371Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: GrantFiled: December 10, 2010Date of Patent: July 22, 2014Assignee: Cedars-Sinai Medical CenterInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 8784866Abstract: Compositions comprising a plurality of functionalized carbon nanotubes and at least one type of payload molecule are provided herein. The compositions are soluble in water and PBS in some embodiments. In certain embodiments, the payload molecules are insoluble in water. Methods are described for making the compositions and administering the compositions. An extended release formulation for paclitaxel utilizing functionalized carbon nanotubes is also described.Type: GrantFiled: October 3, 2008Date of Patent: July 22, 2014Assignees: William Marsh Rice University, Board of Regents, The University of Texas SystemInventors: James M. Tour, Rebecca Lucente-Schultz, Ashley Leonard, Dmitry V. Kosynkin, Brandi Katherine Price, Jared L. Hudson, Jodie L. Conyers, Jr., Valerie C. Moore, S. Ward Casscells, Jeffrey N. Myers, Zvonimir L. Milas, Kathy A. Mason, Luka Milas
-
Patent number: 8784849Abstract: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.Type: GrantFiled: February 11, 2013Date of Patent: July 22, 2014Assignee: Nektar TherapeuticsInventors: Michael J. Roberts, Antoni Kozlowski
-
Patent number: 8784791Abstract: A method is provided for preparing water-soluble polymer derivatives bearing a terminal N-succinimidyl ester. The method involves the hydrolyzing an ortho ester of a water-soluble polymer so as provide the corresponding acid and subsequently esterifying the acid.Type: GrantFiled: April 4, 2013Date of Patent: July 22, 2014Assignee: Nektar TherapeuticsInventor: Antoni Kozlowski
-
Patent number: 8778325Abstract: A water-soluble and biodegradable antimicrobial agent is provided, comprising a polymer composed of a segment A and a segment B, in which, the segment A has the following formula I: the segment B has the following formula II: wherein the segment A and the segment B in the polymer have a molar ratio of 1:0.007-1.2, and n is 0 or 1, m is an integer of 0-2, m+n?0, X is H, Na, K, NH4, ½Ca, or ½Mg, and Y is Cl, Br, or I.Type: GrantFiled: May 2, 2011Date of Patent: July 15, 2014Assignee: Far Eastern New Century CorporationInventors: Chun-Yi Li, Ken-Yuan Chang, Chia-Chang Liu, Ying-Nan Tsai
-
Publication number: 20140193356Abstract: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Applicant: The Board of Regents, The University of Texas SystemInventor: Jian Yang
-
Patent number: 8771662Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: February 12, 2013Date of Patent: July 8, 2014Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 8765112Abstract: The invention relates to materials comprising siloxanes, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement.Type: GrantFiled: April 18, 2008Date of Patent: July 1, 2014Assignee: University of MassachusettsInventors: Jie Song, Jianwen Xu
-
Patent number: 8758740Abstract: Provided is a composition for promoting ketone body production that comprises a water insoluble polymer of a ?-hydroxy short-medium chain fatty acid such as homopolymer of ?-hydroxybutyric acid or a copolymer of ?-hydroxybutyric acid and ?-hydroxyvaleric acid. The composition is useful for the treatment or prevention of a disease or condition that can be treated by promoting ketone body production.Type: GrantFiled: March 31, 2008Date of Patent: June 24, 2014Assignee: Earthus, IncInventor: Masaki Kuriyama
-
Publication number: 20140172117Abstract: An antithrombotic material has an excellent anticoagulant activity and can form a stable coating layer on a base material through a simple and mild coating process. An antithrombotic material includes a copolymer configured to have 75% by mole to 25% by mole of a repeating unit (A) derived from diacetone(meth)acrylamide represented by the following formula (1) (wherein R1 is a hydrogen atom or a methyl group) and 25% by mole to 75% by mole of a repeating unit (B) derived from a monomer having at least one sulfonate group selected from a group consisting of 2-(meth)acrylamide-2-methyl-propane sulfonic acid, vinyl sulfate, allyl sulfate, styrenesulfonic acid, sulfoethyl(meth)acrylate, and sulfopropyl(meth)acrylate in a molecule, or a salt of the monomer (the total amount of the repeating unit (A) and the repeating unit (B) is 100% by mole).Type: ApplicationFiled: February 21, 2014Publication date: June 19, 2014Applicant: TERUMO KABUSHIKI KAISHAInventors: Takao ANZAI, Tomoe HAKAMATANI
-
Publication number: 20140161762Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20140154203Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.Type: ApplicationFiled: November 22, 2013Publication date: June 5, 2014Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Patent number: 8741325Abstract: The present invention provides a material for forming an antimicrobial surface coating with multi-level antimicrobial properties, which comprises one or more volatile or gaseous biocides, one or more nonvolatile biocides, and one or more polymers, wherein the volatile or gaseous biocides are encapsulated in the polymers to provide a sustained release of the volatile or gaseous biocides. The present invention further provides a method for preparing the material.Type: GrantFiled: December 4, 2009Date of Patent: June 3, 2014Assignee: The Hong Kong University of Science and TechnologyInventors: King Lun Yeung, Wai Kin Leung
-
Patent number: 8728453Abstract: The present invention is directed towards the synthesis of polymeric drug delivery compositions which would address some of the important and difficult to realize aspects of polymer based drug delivery systems by being, biocompatible, stable, capable of achieving desired drug loading, and safe from accidental release while being non-toxic, easy to fabricate and safe for the environment.Type: GrantFiled: February 28, 2012Date of Patent: May 20, 2014Assignee: Innovotech, LLCInventor: Falguni Dasgupta
-
Publication number: 20140134127Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: ApplicationFiled: January 16, 2014Publication date: May 15, 2014Applicant: MERSANA THERAPEUTICS, INC.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dmitry R. Gumerov
-
Patent number: 8715708Abstract: A novel class of Cylic Acetal biomaterials (CABs) based on a cyclic acetal unit is disclosed and claimed by Applicants. Two novel biomaterials suitable for use in a variety of biological applications including in the orthopedic field for joint and cartilage replacement and/or repair, and bone cement. The biomaterials are comprised of either a network of monomers of 5-ethyl-5-(hydroxymethyl)-?,?-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD) and a hydrogel comprised of EHD and poly(ethylene glycol) diacrylate (PEG-EHD).Type: GrantFiled: August 31, 2006Date of Patent: May 6, 2014Assignee: University of MarylandInventors: John Patrick Fisher, Sachiko Kaihara, Jennifer Lynn Moreau, Parth Modi
-
Patent number: 8715635Abstract: A rotaxane consisting of a cucurbituril and an uncharged guest molecule, having low or null affinity therebetween is provided as well as processes for providing the same. Various uses as energy converters (“frictionless” molecular motors), biochips and biosensors using the same are also provided.Type: GrantFiled: February 6, 2008Date of Patent: May 6, 2014Assignee: Technion Research & Development Foundation LimitedInventor: Ehud Keinan
-
Publication number: 20140120053Abstract: A therapeutic agent delivery system formed of a specific type of poly(ester amide) (PEA), a therapeutic agent, and a water miscible solvent is described herein. A method of delivering the therapeutic agent delivery system by delivering the therapeutic agent delivery system formed of a PEA polymer, a therapeutic agent, and a water miscible solvent to a physiological environment and separating the phase of the therapeutic agent delivery system to form a membrane from the polymer to contain the therapeutic agent within the physiological environment is also described. Additionally disclosed is a kit including a syringe and a therapeutic agent delivery system within the syringe.Type: ApplicationFiled: January 7, 2014Publication date: May 1, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Lothar W. Kleiner, Syed Hossainy, Stephen Pacetti, Jessica DesNoyer
-
Patent number: 8703293Abstract: Provided herein re a composition and a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.Type: GrantFiled: April 1, 2010Date of Patent: April 22, 2014Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Lothar W. Kleiner, Connie S. Kwok
-
Patent number: 8703113Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.Type: GrantFiled: January 18, 2006Date of Patent: April 22, 2014Assignee: REVA Medical Inc.Inventors: Donald K. Brandom, James E. McGrath, Joan Zeltinger, Eric V. Schmid, Robert K. Schultz
-
Patent number: 8703114Abstract: Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.Type: GrantFiled: May 21, 2009Date of Patent: April 22, 2014Assignees: Ramot at Tel-Aviv University Ltd., University of Utah Research FoundationInventors: Ronit Satchi-Fainaro, Ehud Segal, Jindrich Kopecek, Pavla Kopeckova, Huaizhong Pan
-
Patent number: 8703115Abstract: The present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a conjugate having a degradable linkage. The conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods for delivering such compositions are also provided.Type: GrantFiled: March 7, 2013Date of Patent: April 22, 2014Assignee: Nektar TherapeuticsInventors: Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
-
Publication number: 20140099263Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: March 19, 2013Publication date: April 10, 2014Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Thomas C. Crawford, Geeti Gangal, Lawrence Alan Reiter, Pei-Sze Ng
-
Publication number: 20140099278Abstract: A polycaprolactone fumarate polymer useful as a matrix material for a biocompatible scaffold for tissue engineering applications is disclosed. The polycaprolactone fumarate polymer can be prepared by reacting caprolactone with an alkane polyol to prepare a polycaprolactone precursor, and then reacting the polycaprolactone precursor with fumaric acid or a salt thereof to prepare the polycaprolactone fumarate polymer. The use of an alkane diol, such as 1,2-propanediol, provides a linear polycaprolactone diol precursor. The use of an alkane triol, such as glycerol, provides a branched polycaprolactone triol precursor. The biocompatible polycaprolactone fumarate formulation releases no diethylene glycol or other undesirable byproducts during degradation.Type: ApplicationFiled: April 4, 2012Publication date: April 10, 2014Inventors: Michael Brett Runge, Michael J. Yaszemski
-
Patent number: 8691918Abstract: The present invention provides novel and improved stimulus responsive polymers and methods of using the same for the purification of biomolecules.Type: GrantFiled: May 16, 2011Date of Patent: April 8, 2014Assignee: EMD Millipore CorporationInventors: Jad Jaber, Wilson Moya, James Hamzik, Arezki Boudif, Yu Zhang, Neil Soice, John Charkoudian, Nripen Singh
-
Patent number: 8691899Abstract: An antimicrobial composition and a medical device having that antimicrobial composition that includes a complex of an anionic polyester with a monomeric amidoamine having at least one amide group and at least one amine group, wherein the amine group is either a primary amine, or a secondary amine, or a tertiary amine, or a quaternary amine, or a combination thereof and the anionic polyester has at least one carboxylic group.Type: GrantFiled: October 9, 2007Date of Patent: April 8, 2014Assignee: Ethicon, Inc.Inventors: Modesto Erneta, Joerg Priewe
-
Patent number: 8691204Abstract: This invention relates, e.g., to a composition suitable for administration to the central nervous system (CNS), comprising a block copolypeptide hydrogel, which comprises a biologically active material that is mixed with the hydrogel or that is attached to the polypeptide chain of the hydrogel, wherein the composition is suitable for administration to the CNS. Also disclosed are methods of making and using compositions of the invention as depots or as scaffolds for cell migration, and pharmaceutical compositions and kits for implementing methods of the invention.Type: GrantFiled: February 18, 2010Date of Patent: April 8, 2014Assignee: The Regents of the University of CaliforniaInventors: Timothy J. Deming, Michael V. Sofroniew, Chu-Ya Yang, BingBing Song, Yan Ao
-
Publication number: 20140093473Abstract: The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid.Type: ApplicationFiled: December 31, 2012Publication date: April 3, 2014Inventors: Charlotte Hauser, Yihua Loo
-
Patent number: 8685383Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: GrantFiled: June 11, 2012Date of Patent: April 1, 2014Assignee: Mersana Therapeautics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dmitry R. Gumerov
-
Patent number: 8685382Abstract: The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly poly (hydroxyalkyl(meth) acrylamide mono/di-lactate_interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer's solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation.Type: GrantFiled: September 23, 2011Date of Patent: April 1, 2014Assignee: Cristal Delivery B.V.Inventors: Wilhelmus Everhardus Hennink, Cornelis Franciscus Van Nostrum, Marinus Jacob Van Steenbergen, Osamu Soga, Cristianne Johanna Ferdinand Rijcken
-
Publication number: 20140086865Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.Type: ApplicationFiled: December 2, 2013Publication date: March 27, 2014Applicants: The State of Oregon Acting by and through the State Board of Higher Ed. on Behalf of Oregon Stat, ALLVIVO VASCULAR, INC.Inventors: Pranav Joshi, Joseph McGuire, Jennifer A. Neff
-
Patent number: 8679536Abstract: Adhesives formed by reacting an oxidized polysaccharide with a poly(hydroxylic) compound derivatized with acetoacetate groups in the presence of a base catalyst are disclosed. The use of the adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; and drug delivery are described. The adhesive may also be used for industrial and consumer applications.Type: GrantFiled: August 24, 2006Date of Patent: March 25, 2014Assignee: Actamax Surgical Materials, LLCInventor: Samuel David Arthur
-
Patent number: 8679537Abstract: Methods for sealing an orifice in tissue in the body of a living animal using an adhesive formed by reacting an oxidized polysaccharide with a poly(hydroxylic) compound derivatized with acetoacetate groups in the presence of a base catalyst are disclosed. Methods for using the adhesive for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; and drug delivery are described.Type: GrantFiled: August 24, 2006Date of Patent: March 25, 2014Assignee: Actamaz Surgical Materials, LLCInventor: Samuel David Arthur
-
Patent number: 8674033Abstract: The invention is directed to biodegradable, thermoplastic, phase separated segmented multi-block copolymers. The copolymers of the present invention find use in various biomedical applications as well as in pharmaceutical applications. According to the invention, a biodegradable, phase separated copolymer is provided, comprising segments of a soft prepolymer (A) having a glass transition temperature, Tg, lower than 37° C.; and segments of a hard prepolymer (B) having a phase transition temperature, Tm, of 40-100° C.Type: GrantFiled: July 16, 2003Date of Patent: March 18, 2014Assignee: Innocore Technologies B.V.Inventors: Catharina Everdina Hissink, Ronald Meyboom, Theodorus Adrianus Cornelius Flipsen
-
Publication number: 20140072604Abstract: To provide a therapeutic method using a water soluble, high molecular weight block polymer to enable that an intraperitoneally administered anti-cancer agent may maintain for a long-term retention in the abdominal cavity to enoughly exert the effect of the anti-cancer agent and reduce adverse side-effects thereof. A therapeutic agent as a micelle preparation, comprising a copolymer having a hydrophilic polymeric moiety and a polycarboxylic acid derivative moiety; and an anti-cancer agent bonding to or encapsulated in the copolymer, wherein the micelle preparation may exhibit sustained drug release capability, and enables an extension of a retention time period of the anti-cancer agent in an abdominal cavity, is provided. A superior life-prolonging effect was found in an intraperitoneal administration mouse model compared with a case in which only an encapsulated drug is administered, and thus the present invention was completed accordingly.Type: ApplicationFiled: October 22, 2013Publication date: March 13, 2014Applicant: Nippon Kayaku Kabushiki KaishaInventors: Yuichi Akatsu, Hiroko Mashiba
-
Publication number: 20140072633Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer or neurological deficits. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: May 29, 2013Publication date: March 13, 2014Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Thomas C. Crawford, Geeti Gangal, Lawrence Alan Reiter, Pei-Sze Ng
-
Publication number: 20140065199Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.Type: ApplicationFiled: August 29, 2013Publication date: March 6, 2014Applicant: W. L. Gore & Associates, Inc.Inventors: Tiffany J. Brown, Adam S. Lafleur, Kenneth Mazich, Jeffrey C. Towler, Ji Zhang
-
Publication number: 20140065090Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.Type: ApplicationFiled: August 29, 2013Publication date: March 6, 2014Applicant: W. L. Gore & Associates, Inc.Inventors: Tiffany J. Brown, Adam S. Lafleur, Kenneth Mazich, Jeffrey C. Towler, Ji Zhang
-
Publication number: 20140065093Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.Type: ApplicationFiled: November 7, 2013Publication date: March 6, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Wouter E. Roorda, Stephen D. Pacetti
-
Patent number: 8658348Abstract: Methods for modification of tissue using covalent chemistry. Tissue can be modified through direct alkylation, reduction followed by alkylation, or oxidation followed by condensation to covalently attach small organic molecules or appropriately modified proteins. The modification can be spatially limited to desired regions of the tissue surface.Type: GrantFiled: August 9, 2011Date of Patent: February 25, 2014Assignee: Baylor UniversityInventors: Robert R. Kane, Aruna Perera
-
Patent number: 8658192Abstract: Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, and methods for making and using the cationic polymers and surfaces. The cationic polymers include counterions and/or hydrolyzable groups that release active agents.Type: GrantFiled: October 14, 2010Date of Patent: February 25, 2014Assignee: University of WashingtonInventors: Shaoyi Jiang, Gang Cheng, Luo Mi, Hong Xue, Yuting Li
-
Patent number: 8658149Abstract: Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.Type: GrantFiled: May 21, 2009Date of Patent: February 25, 2014Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ronit Satchi-Fainaro, Keren Miller, Doron Shabat, Rotem Erez
-
Publication number: 20140050689Abstract: Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed.Type: ApplicationFiled: February 8, 2013Publication date: February 20, 2014Applicant: Pathak Holdings LLCInventors: Chandrashekhar P. Pathak, Sanjay M. Thigle
-
Publication number: 20140050690Abstract: There is provided a beraprost sodium-containing nanoparticle that contains beraprost sodium among other prostaglandin I2 (prostacyclin) derivatives, which are therapeutic agents for pulmonary hypertension. The beraprost sodium-containing nanoparticle is obtained by making beraprost sodium hydrophobic using a metal ion and allowing the hydrophobic beraprost sodium to react with poly-L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer, and a poly-DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer. The beraprost sodium-containing nanoparticle excels in sustained release of an active ingredient, reduces a side effect, and furthermore, has an excellent drug retention in the blood. Therefore, the beraprost sodium-containing nanoparticle is quite outstanding particularly regarding the sustainability of the medicinal effect.Type: ApplicationFiled: February 13, 2012Publication date: February 20, 2014Applicant: LTT Bio-Pharma Co., Ltd.Inventors: Toru Mizushima, Tsutomu Ishihara, Hongxing Liu
-
Patent number: 8642023Abstract: Problem To provide a skin cosmetic which exerts a feeling of ameliorating effect on skin wrinkles and sagging by application, and is free from uncomfortable feelings in use, such as stickiness, twisting of the cosmetic applied on the skin, and squeakiness. Means for Solution A skin cosmetic is provided, which comprises an aqueous liquid of an anionic or amphoteric urethane resin dissolved or dispersed in water and wherein the anionic or amphoteric urethane resin is prepared by reacting (a) an isocyanate compound with (b) a polyol compound containing the following components (b-1) to (b-3) or the following components (b-1) to (b-4) and having a ratio of (b-1)/(b-2) of 0.15-3.0 (by mass, in terms of charge): [(b-1): cyclohexanedimethanol, (b-2): polypropylene glycol having a molecular weight of 1000-3000, (b-3): a compound having an active hydrogen and a carboxyl group in one molecule, (b-4): a compound having an active hydrogen and a tertiary amino group in one molecule.].Type: GrantFiled: November 12, 2008Date of Patent: February 4, 2014Assignee: Shiseido Company, Ltd.Inventors: Takayuki Omura, Mihoshi Yokoo
-
Patent number: 8642086Abstract: A composition of matter comprises a cationic polymer comprising a polycarbonate chain fragment, the polycarbonate chain fragment comprising a repeat unit comprising a side chain moiety containing a quaternary amine group; and a non-charged polymer comprising a polyester chain segment and a poly(alkylene oxide) chain segment; wherein i) the cationic polymer and the non-charged polymer are amphiphilic and biocompatible, ii) the cationic polymer and the non-charged polymer form a mixed complex by non-covalent interactions in water, and iii) the mixed complex is a more effective antimicrobial agent against at least a Gram-negative microbe compared to the cationic polymer and the non-charged polymer alone when tested using otherwise identical conditions.Type: GrantFiled: March 31, 2011Date of Patent: February 4, 2014Assignees: International Business Machines Corporation, Agency for Science, Technology and ResearchInventors: Daniel Joseph Coady, Kazuki Fukushima, James Lupton Hedrick, Yi Yan Yang